The announcement is not capable of being marked price sensitive as it gives no financial details around the sponsorship agreement. Either this is because they remain subject to negotiation and/or because they are considered trade sensitive by either party. Additionally the "first right of negotiation to license Penn intellectual property arising from the conduct of the sponsored research" is an agreement for a potential future negotiation of purchase of IP and therefor the ASX would not consider that information price sensitive.
- Forums
- ASX - By Stock
- CHM
- Ann: Sponsored Research Agreement with University of Pennsylvania
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Ann: Sponsored Research Agreement with University of Pennsylvania, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $10.32K | 2.580M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 4130543 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 18587873 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 4280543 | 0.004 |
40 | 26959271 | 0.003 |
16 | 15400505 | 0.002 |
12 | 54600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 18587873 | 22 |
0.006 | 13384684 | 15 |
0.007 | 3100000 | 2 |
0.008 | 8542434 | 6 |
0.009 | 2390797 | 5 |
Last trade - 11.38am 27/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online